Global Cystic Fibrosis Market Analysis & Forecasts 2024-2034: Focus on Mucolytics, Bronchodilators, Cystic Fibrosis Transmembrane Conductance Regulator Modulators, & Pancreatic Enzyme Supplements
June 13, 2024 10:08 ET
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global cystic...
Pulmonary Fibrosis Treatment Market Research: Escalating Demand for Innovative Treatment Options Amidst Escalating Prevalence - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031
May 24, 2024 03:29 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Surrozen Provides First Quarter 2024 Financial Results and Business Update
May 08, 2024 16:05 ET
|
Surrozen, Inc.
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Global Cystic Fibrosis Market Analysis & 10 Year Forecast 2024-2034: By Drug Class, CFTR Modulators was the Highest Revenue-Grossing Segment in the Global Cystic Fibrosis Market in 2023
April 09, 2024 04:13 ET
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global cystic...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
November 29, 2023 17:41 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market...
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
April 11, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, April 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today reported...
Global Spirometer Market is projected to be worth US$ 616 Million in 2023 and is further poised to grow at a CAGR of 5.4% to hit US$ 1042.3 Million by 2033 end | Future Market Insights, Inc.
March 28, 2023 10:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 28, 2023 (GLOBE NEWSWIRE) -- The global spirometer market size is set to reach US$ 616 million in 2023. Overall sales of spirometer are likely to surge at 5.4% CAGR, taking the...
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
March 23, 2023 13:23 ET
|
Avalyn Pharma Inc.
SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
November 28, 2022 12:00 ET
|
Avalyn Pharma Inc.
SEATTLE , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Paving the way for better diagnosis, treatment and care in pulmonary fibrosis
November 11, 2022 10:32 ET
|
Three Lakes Foundation; Vanderbilt University Medical Center; Radiomics
NORTHBROOK, Ill., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Three Lakes Foundation has announced the expansion of B4PF, an initiative focused on at-risk individuals for ILD/PF, early diagnosis and...